Research & Regulatory News

TRIUMPH-6: Maintenance of Weight Reduction

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

TRIUMPH-6 (NCT06859268) is a Phase 3 trial of retatrutide in the maintenance of weight reduction, enrolling 643 participants. It began in March 2025 and has a primary completion date of April 2028. The field's most important open question therefore has no answer for several years.

Key facts

Registration
NCT06859268
Acronym
TRIUMPH-6
Focus
Maintenance of weight reduction
Phase
3
Enrolment
643 participants
Started
5 March 2025
Primary completion
April 2028
Status
Active, not recruiting

The question it addresses

Every headline figure in this field describes weight while treatment continues. What happens afterwards is measured far less often, and where it has been measured the answer is uncomfortable: the STEP-1 extension found roughly two-thirds of the loss returning within a year of stopping semaglutide. Maintenance dosing asks whether a reduced dose can hold the result without the full treatment burden.

Why the completion date matters

TRIUMPH-6 has a primary completion date of April 2028. That needs saying clearly, because commentary tends to describe maintenance data as imminent, or as the thing the field is currently waiting on. It is neither. It is several years out, and until then every claim about durability rests on extrapolation from other compounds.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why maintenance trials take so long

The design requires participants to reach a reduction plateau first, then be randomised to a maintenance strategy, then be followed long enough for divergence to appear. That is three sequential phases rather than one. A 12-month endpoint measured after a 12-month run-in is a two-year trial before analysis, which is why maintenance evidence lags efficacy evidence across the whole class by years.

What this means for reading efficacy figures

A peak reduction figure describes a maintained state, not an achieved outcome. Retatrutide's 28.3% at 80 weeks is the reduction present while treatment continued at 12 mg. Whether any of it persists at a lower dose, or without treatment, is exactly what TRIUMPH-6 exists to find out and will not report until 2028. Reading peak figures as durable results is the single most common error in coverage of this field.

Scale and status

The trial enrolled 643 participants and began on 5 March 2025. It is listed as active but no longer recruiting. Retatrutide remains investigational in every jurisdiction throughout.

Frequently asked questions

When will maintenance data be available?

TRIUMPH-6 has a primary completion date of April 2028, with publication following after that.

Is maintenance data available for any incretin?

Cessation data exists (the STEP-1 extension is the best known), but purpose-built maintenance-dosing trials are still reading out across the class.

Why do maintenance trials take longer than efficacy trials?

They need a reduction phase, then randomisation to a maintenance strategy, then long follow-up. Three sequential stages instead of one.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.